ArticlePharmaceuticals (Basel, Switzerland)2015
Prospects for Anti-Biofilm Pharmaceuticals.
Article in Pharmaceuticals (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Measuring Antimicrobial Efficacy against Biofilms: a Meta-analysis.Antimicrobial agents and chemotherapy · 2019Pooled it
- Papain: an antimicrobial enzyme of Papaya latex inhibits the production of biofilm and disrupts pre-formed biofilm matrix of Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- Translating microbial knowledge into clinical biofilm therapies.Open medicine (Warsaw, Poland) · 2026Review
- Emerging Multimodal Strategies for Bacterial Biofilm Eradication: A Comprehensive Review.Microorganisms · 2025Review
- Sophorolipid: An Effective Biomolecule for Targeting Microbial Biofilms.Current microbiology · 2024Review
- Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities.Clinical microbiology reviews · 2024Review
- Small Schiff Base Molecules-A Possible Strategy to Combat Biofilm-Related Infections.Antibiotics (Basel, Switzerland) · 2024Review
- α,α-disubstituted β-amino amides eliminateBiofilm · 2023Article
- KACS omega · 2023Article
- Efficient Inhibition of Bacterial Biofilm Through Interference of Protein-Protein Interaction of Master Regulator Proteins: a Proof of Concept Study with SinR- SinI Complex of Bacillus subtilis.Applied biochemistry and biotechnology · 2023Article
- An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents.Life (Basel, Switzerland) · 2022Review
- One Health-One Biofilm.Veterinary research · 2022Article
- Recent Strategies to Combat Biofilms Using Antimicrobial Agents and Therapeutic Approaches.Pathogens (Basel, Switzerland) · 2022Review
- Prevalence and Impact of Biofilms on Bloodstream and Urinary Tract Infections: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2021Article
- Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.Frontiers in cellular and infection microbiology · 2021Review
- Inhibition of Virulence Factors and Biofilm Formation of Acinetobacter Baumannii by Naturally-derived and Synthetic Drugs.Current drug targets · 2021Review
- Biofilm Inhibitor Taurolithocholic Acid Alters Colony Morphology, Specialized Metabolism, and Virulence ofACS infectious diseases · 2020Article
- Targeting Bacterial Biofilms by the Green Tea Polyphenol EGCG.Molecules (Basel, Switzerland) · 2019Review
- Antagonistic effect of ursolic acid onVeterinary world · 2018Article
- Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action.Virulence · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromised niches within the body. Strategies being researched include discovering new antimicrobial agents that kill microorganisms in biofilms more effectively than do existing antibiotics, designing drugs that block microbial adhesion or interfere with intercellular communication, developing chemistries to disperse biofilms, and combining agents with different mechanisms of action. Though the need is great, the pathway to commercialization of new drugs is steep. One possible streamlined approach to navigating the regulatory approval process is to repurpose old drugs, a strategy that a few groups have shown can yield agents with anti-biofilm properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.